Pilot studies of ethyl-EPA in the treatment
of anorexia nervosa

Ayton, A.K., Azaz, A., Horrobin, D.F. (2004) Prostaglandins Leukot Essent Fatty Acids. 71(4) 205-9

Abstract: Anorexia nervosa (AN) carries the highest risk of morbidity and mortality amongst psychiatric disorders. The efficacy of current treatment approaches is limited. Despite the fat-phobic nature of the disease, poly-unsaturated fatty acids (PUFAs) have not received much research attention. Patients who consume western diet, which is rich in n-6 PUFAs and trans-fatty acids, are likely to develop severe n-3 PUFA deficiency during self-induced starvation. Re-feeding programmes do not take into consideration n-3 EFA intake, possibly leading to further n-3 PUFA deficiency during weight restoration, and this might contribute to the maintenance of the disorder. To test this hypothesis, we carried out a systematic case series of E-EPA supplementation in the treatment of AN. Seven young patients received 1g/day E-EPA in addition to standard treatment, and were followed up for 3 months. Three of them recovered and four improved. Randomised controlled trials are warranted to examine the effectiveness of E-EPA in AN further.

• The healthy fats
  -- read
  
  
• Omega-3 linked to lower colorectal cancer risk
  -- read
  
  
• Omega-3 greater anti-inflammatory potential
  -- read
  
  
• Marine omega-3 fatty acids are the preferred source of EPA and DHA in humans
  -- read
  
  
• Quality and Safety of omega-3 products
  -- read
  
  
• Omega-3 Fatty Acids
  -- read
  
  
• Preventing skin damage in the sun
  -- read
  
  
• Preventing obesity and obesity-related diseases
  -- read
  
  
• Pilot studies of ethyl-EPA in the treatment of anorexia nervosa
  -- read
  
  
• A vast range of applications
  -- read
  
  
• Research in various health fields
  -- read